| abstract |
The use of a tumor suppressor nucleic acid which is a nucleic acid that encodes a tumor suppressor protein comprising a native p53 protein or a retinoblastoma protein, in combination with a polyprenyl protein transferase inhibitor, a selected geranylgeranyl-protein transferase inhibitor or a farnesyl-protein transferase inhibitor that is selected from the group consisting of FPT39, farnesylated peptidomimetic compound, condensed heterocyclic benzocycloheptapyridine and farnesyl derivative, for the preparation of a pharmaceutical composition for the treatment of mammalian cancerous or hyperproliferative cells. Furthermore, a chemotherapeutic agent may be present. |